NDAINHALATIONPOWDERPriority Review
Approved
Jul 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
17
Data completeness
4/8 — Partial
Priority Review
RELENZA (zanamivir) by GSK is neuraminidase inhibitors [moa]. First approved in 1999.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
RELENZA (zanamivir) is an inhaled neuraminidase inhibitor approved in 1999 for the treatment of influenza and related viral diseases. It works by blocking the neuraminidase enzyme on the influenza virus surface, preventing viral release from infected cells. The drug is administered as an inhalation powder, offering a non-systemic delivery route distinct from oral antivirals.
$0.013BPart D
LOE ApproachingDeclining
Declining Part D utilization and approaching loss of exclusivity signal a contracting commercial footprint and reduced team expansion opportunities.
Mechanism of Action
Neuraminidase Inhibitors
Pharmacologic Class:
Neuraminidase Inhibitor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (17)
An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza Infection
Started Nov 2022
12 enrolled
Influenza, HumanArthralgia
Pharmacokinetics of Zanamivir After Single and Repeated Dose Infusion Administration in Healthy Chinese Adults
Started Apr 2015
24 enrolled
Influenza, Human
A Study of Intravenous Zanamivir in the Treatment of Hospitalized Patients With Influenza Infection
Started Jan 2012
21 enrolled
Influenza, Human
Safety of Inhaled Zanamivir in Pregnancy
Started Jul 2011
1 enrolled
Influenza, Human
Zanamivir Aqueous Solution Compassionate Use Program Retrospective Chart Review Study
Started Jul 2011
113 enrolled
Infections, Respiratory Tract
Worked on RELENZA at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.